Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA Study: FOLFOX plus panitumumab vs 5‑FU plus panitumumab in elderly RAS/BRAF wild‑type metastatic colorectal cancer
2015-003888-10Phase 2Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of panitumumab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Progression-free survival. Started Sep 2021; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2015-003888-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003888-10.